Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Analyst Ratings
  • Markets
  • News
  • Price Target
  • Trading Ideas

Nvidia To Rally Around 53%? Here Are 10 Top Analyst Forecasts For Tuesday

By Avi Kapoor
June 18, 9:44 AM
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…

ABBV

Read More
2 minute read
  • Markets
  • Media
  • News
  • Trading Ideas

Nvidia, AbbVie, Vertex Pharmaceuticals And An Oil Giant: CNBC’s ‘Final Trades’

By Avi Kapoor
June 17, 8:47 AM
On CNBC's Halftime Report, Bryn Talkington picked NVIDIA, Jim Lebenthal chose Vertex Pharmaceuticals, Kevin Simpson named ConocoPhillips, and Rob Sechan suggested AbbVie, with all four stocks having recent news and price changes.

ABBV

Read More
2 minute read
  • Short Ideas
  • Short Sellers
  • Trading Ideas

Looking Into AbbVie’s Recent Short Interest

By Benzinga Insights
June 13, 9:45 AM
AbbVie’s (NYSE:ABBV) short percent of float has risen 3.33% since its last report. The company recently reported that…

ABBV

Read More
5 minute read
  • Options

10 Health Care Stocks With Whale Alerts In Today’s Session

By Benzinga Insights
June 11, 1:35 PM
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…

ABBV

Read More
3 minute read
  • Markets
  • News
  • Trading Ideas

Comparative Study: AbbVie And Industry Competitors In Biotechnology Industry

By Benzinga Insights
June 11, 11:00 AM
In today’s fast-paced and highly competitive business world, it is crucial for investors and industry followers to conduct…

ABBV

Read More
2 minute read
  • Analyst Color
  • Analyst Ratings
  • Initiation
  • Movers
  • News
  • Price Target
  • Top Stories
  • Trading Ideas

Goldman Sachs Optimistic About Regenxbio’s Gene Therapy Pipeline, Sees Over 160% Upside

By Vandana Singh
June 7, 2:30 PM
Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.

ABBV

Read More
4 minute read
  • Options

10 Health Care Stocks With Whale Alerts In Today’s Session

By Benzinga Insights
June 7, 1:35 PM
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…

ABBV

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Media
  • News
  • Top Stories

AbbVie’s Arthritis Drug Humira Retains Market Dominance Despite Biosimilar Competition, Challenges Biosimilar Industry Viability

By Vandana Singh
June 7, 10:39 AM
Humira maintains over 80% of its market share despite facing nine biosimilar rivals, raising concerns about the future of the biosimilar market and prompting calls for regulatory reform to enhance patient access and incentivize development.

ABBV

Read More
2 minute read
  • Long Ideas
  • Markets
  • Media
  • News
  • Trading Ideas

AbbVie, Amazon, Goldman Sachs And 2 Major Health Care Stocks On CNBC’s ‘Final Trades’

By Avi Kapoor
June 7, 8:59 AM
AbbVie Inc. has good dividend yield and attractive valuations, according to Jim Lebenthal of Cerity Partners.

ABBV

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News
  • Top Stories

AbbVie’s Immunogen Acquired Elahere Meets Primary Goal In Mid-Stage Study In Heavily Pretreated Ovarian Cancer Patients

By Vandana Singh
June 6, 1:02 PM
AbbVie announced Phase 2 PICCOLO trial results for Elahere in heavily pre-treated ovarian cancer patients. The trial achieved a 51.9% objective response rate.

ABBV

Posts pagination

1 2 … 38 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service